Literature DB >> 32315652

MiR-19b-3p facilitates the proliferation and epithelial-mesenchymal transition, and inhibits the apoptosis of intrahepatic cholangiocarcinoma by suppressing coiled-coil domain containing 6.

Yi Tang1, Jianrong Yang1, Yonggang Wang2, Zhenyong Tang1, Sulai Liu2, Yuntian Tang3.   

Abstract

BACKGROUND: Intrahepatic cholangiocarcinoma (ICC) is the second most common primary hepatocellular carcinoma, and microRNAs (miRNAs) play a vital role in its development. This study aimed to explore the molecular mechanism and clinical value of miR-19b-3p in ICC.
METHODS: From March 2014 to October 2016, 94 pairs of specimens of ICC tissues and adjacent tissues were collected. Moreover, 5 ml of peripheral blood of 342 ICC patients who underwent ICC resection were collected before and one week after surgery. Luciferase activity assay was performed to confirm the regulation of miR-19b-3p on coiled-coil domain containing 6 (CCDC6). BALB/c nude mice were injected with CCLP-1 cells which were transfected with NC, miR-19b-3p mimic, miR-19b-3p inhibitor, pcDNA-CCDC6, si-CCDC6 or miR-19b-3p mimic + pcDNA-CCDC6.
RESULTS: Results showed that miR-19b-3p levels were significantly higher in ICC tissues compared with adjacent tissues. Moreover, serum miR-19b-3p levels of ICC patients tended to decline after surgery, and were correlated with lymph node metastasis and histological grading of ICC. CCDC6, a new target gene of miR-19b-3p, was identified by four prediction databases. We confirmed that miR-19b-3p promoted cell proliferation and epithelial-mesenchymal transition (EMT), and inhibited apoptosis in ICC, while knockdown of CCDC6 reversed these effects. We also observed that miR-19b-3p/CCDC6 axis regulated the nuclear translocation of β-catenin. Furthermore, in vivo study also demonstrated that the miR-19b-3p/CCDC6 axis regulated EMT to promote ICC progression.
CONCLUSION: These results indicate that serum miR-19b-3p level is a crucial biomarker for ICC diagnosis and targeting miR-19b-3p-CCDC6 axis might be a promising strategy in ICC therapy.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Coiled-coil domain containing 6; Epithelial-mesenchymal transition; Intrahepatic cholangiocarcinoma; microRNA

Mesh:

Substances:

Year:  2020        PMID: 32315652     DOI: 10.1016/j.abb.2020.108367

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  6 in total

1.  MiR-19b-3p promotes tumor progression of non-small cell lung cancer via downregulating HOXA9 and predicts poor prognosis in patients.

Authors:  Zu-Lei Li; Dong Li; Guo-Qiang Yin
Journal:  Histol Histopathol       Date:  2022-03-11       Impact factor: 2.130

2.  Upregulation of miR-138 Increases Sensitivity to Cisplatin in Hepatocellular Carcinoma by Regulating EZH2.

Authors:  Taohui Zeng; Lin Luo; Yuye Huang; Xiaoli Ye; Jinhai Lin
Journal:  Biomed Res Int       Date:  2021-03-06       Impact factor: 3.411

3.  MicroRNA miR-19b-3p mediated G protein γ subunit 7 (GNG7) loss contributes lung adenocarcinoma progression through activating Hedgehog signaling.

Authors:  Xia Zhao; Xiang-Cheng Zhang; Kui Zang; Zhi-Hao Yu
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

4.  Synchronized early gastric cancer occurred in a patient with serrated polyposis syndrome: A case report.

Authors:  Ying-Ze Ning; Guan-Yi Liu; Xiao-Long Rao; Yong-Chen Ma; Long Rong
Journal:  World J Clin Cases       Date:  2022-03-16       Impact factor: 1.337

Review 5.  OncomiRs as noncoding RNAs having functions in cancer: Their role in immune suppression and clinical implications.

Authors:  Khalid Otmani; Redouane Rouas; Philippe Lewalle
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

6.  Tumor-derived exosomal miR-19b-3p facilitates M2 macrophage polarization and exosomal LINC00273 secretion to promote lung adenocarcinoma metastasis via Hippo pathway.

Authors:  Jing Chen; Kai Zhang; Yingru Zhi; Yin Wu; Baoan Chen; Jinyu Bai; Xuerong Wang
Journal:  Clin Transl Med       Date:  2021-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.